KAKKIS EMIL D 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Dec 11, 2024
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO
Transactions
- Gift
Common Stock
2024-12-09−20,000→ 2,203,985 total(indirect: By Trust) - Sale
Common Stock
2024-12-10$50.00/sh−8,273$413,650→ 2,195,712 total(indirect: By Trust)
Holdings
- 564,605
Common Stock
Footnotes (2)
- [F1]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F2]Includes 8 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2024.